



NDA 21880/S-052  
NDA 21880/S-053

**SUPPLEMENT APPROVAL**

Celgene  
Attention: Lisa Suttner, MS, RAC  
Director, Regulatory Affairs  
86 Morris Ave  
Summit, NJ 07901

Dear Ms. Suttner:

Please refer to your Supplemental New Drug Applications (S-052) dated November 1, 2017, received November 2, 2017, (S-053) dated November 3, 2017, received November 3, 2017 and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Revlimid® (lenalidomide) Capsules, 2.5, 5, 10, 15, 20 and 25 mg.

We also refer to our letter dated October 12, 2017, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for thalidomide-analogue immunomodulatory agents. This information pertains to the risk of increased mortality with the addition of pembrolizumab, a programmed death receptor-1 (PD-1) blocking monoclonal antibody, to standard multiple myeloma treatment with a thalidomide analogue and dexamethasone.

Supplemental new drug application S-052 provides for revisions to the labeling for Revlimid, consistent with our October 12, 2017 Safety Labeling Change Notification letter.

Supplemental new drug application S-053 provides for the addition of information regarding solid organ transplant rejection to Section 6 ADVERSE REACTIONS, subsection 6.2 Postmarketing Experience of the Prescriber Information.

**APPROVAL & LABELING**

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your November 29, 2017, submission includes final printed labeling (FPL) for your package insert, and Medication Guide. We have not reviewed this FPL. You are responsible for

assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

### **WAIVER OF HIGHLIGHTS SECTION**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

### **CONTENT OF LABELING**

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry (available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Ms. Diane Leaman, Safety Regulatory Project Manager, at (301) 796-1424.

Sincerely,

*{See appended electronic signature page}*

Barry W. Miller  
Deputy Director for Safety (acting)  
Division of Hematology Products  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

BARRY W MILLER  
11/30/2017